A retrospective analysis of the results of the chemotherapy with Docetaxel (DCL) in elderly patients (pts) with metastatic hormone refractory prostate cancer (HRPC) – data from Centre Leon Berard (CLB), Lyon
Article published in Urologia Polska 2008/61/Supl. 1.

authors

Agnieszka Chaładaj, Jean Pierre Droz, Iwona Skoneczna, Tomasz Demkow

Centrum Onkologii – Instytut im. Marii Skłodowskiej-Curie w Warszawie
Centre Leon Berard, Lyon

summary

Introduction.

Prostate cancer is mostly a disease of an older population of pts. At diagnosis, 63.8% of men are ≥65 years old and 27.1%- ≥75 years old. The metastatic hormone- refractory disease is managed by chemotherapy (CHTH) which is a palliative treatment. A great part of pts in this population is frail or vulnerable, and then is at risk of greater toxicity of the CHTH and of worse response to the treatment.

Objectives.

The aim of this study was to evaluate the response to the DCL therapy and the toxicity of this treatment in a population of pts with metastatic HRPC 70 years and more old.

Materials and methods.

We made a retrospective analysis of the chemotherapy with DCL in 37 pts >70 years with metastatic prostate cancer treated at the Centre Leon Berard from 01.01.2005 to 01.01.2007. Median age: 73 (70-80), 13 pts ≥75. The pts received DCL either weekly (25 mg), either every 3 weeks, or weekly then every 3 weeks. The clinical benefit was measured as pain and/or analgesic use decrease, as PR in measurable targets, and in the not evaluable group the CHTH indication was based on survival benefit in asymptomatic pts. We also evaluated the toxicity of the treatment. All pts had a geriatric short screening.

Results.

16 pts (43%) had a clinical benefis, 10 (27%) – didn’t have any benefit and 11 (30%) pts (was not evaluable for the response (asymptomatic pts, no measurable disease). TTP: median 1 month (mo) – (0-8), 7 pts have yet no PD. DOD: 18 pts (48%); median TTDeath: 11 mos (2-24). AWD: 19 pts (51%), median FU: 7 mos (3-27). Toxicities: Hematologic: neutropenia:

Conclusions.

The CHTH by DCL in the metastatic HRPC is well tolerated in the population of pts aged 70 years and more. Due to different CHTH schemas used in CLB and the lack of any selection of the pts in this study (contrary to the population of pts taking part in the clinical studies), the comparison of the efficacy of the DCL in this study with the known results of the efficacy in the clinical studies is not possible.